Citation | Ye, XY; Chen, SY; Wu, S; Yoon, DS; Wang, H; Hong, Z; O'Connor, SP; Li, J; Li, JJ; Kennedy, LJ; Walker, SJ; Nayeem, A; Sheriff, S; Camac, DM; Ramamurthy, V; Morin, PE; Zebo, R; Taylor, JR; Morgan, NN; Ponticiello, RP; Harrity, T; Apedo, A; Golla, R; Seethala, R; Wang, M; Harper, TW; Sleczka, BG; He, B; Kirby, M; Leahy, DK; Li, J; Hanson, RL; Guo, Z; Li, YX; DiMarco, JD; Scaringe, R; Maxwell, B; Moulin, F; Barrish, JC; Gordon, DA; Robl, JA Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11?-Hydroxysteroid Dehydrogenase Type 1 Inhibitor. J Med Chem60:4932-4948 (2017) [PubMed] Article |
---|
SMILES | OC[C@@H]1CCN1C(=O)CC1(C2CC3CC(C2)CC1C3)c1ccc(F)cc1 |r,wU:2.1,TLB:18:17:15:11.12.13,8:9:11.18.12:16.14.15,19:9:15:11.12.13,THB:18:12:9.17.16:15,13:12:9:16.14.15,13:14:9:11.18.12,8:9:15:11.12.13,19:9:11.18.12:16.14.15,(33.65,-5.98,;33.96,-7.49,;35.43,-7.96,;36.13,-9.34,;37.5,-8.64,;36.81,-7.26,;37.29,-5.8,;36.04,-4.88,;38.76,-5.32,;39.91,-6.35,;41.11,-5.07,;42.43,-5.56,;43.83,-5.22,;43.85,-3.69,;42.44,-3.11,;41.1,-3.59,;41.4,-4.35,;41.4,-5.94,;42.82,-6.5,;39.89,-7.89,;38.55,-8.64,;38.53,-10.18,;39.86,-10.97,;39.84,-12.51,;41.2,-10.2,;41.21,-8.66,)| |